>> with $1.50/share in cash or about 40 million, and large trial looming, they will need to raise cash within a year <<
Been watching it trade, since you mentioned it in T/FIF the other day. Looks, to me, as though it is currently being capped by someone who wants shares........ as if there is a seller intent on holding the shares back, not on getting best price. I'll bet there's already a secondary being discussed! Or maybe I'm just shell-shocked by a recent, surprise offering.
Could also be tax-loss selling?
>> oddly, the stock promptly splutted <<
There was sooooooooooo much damage done to development-stage biotechs, April-May. It takes good news and time to recover, and companies which actually have a cash-gobbling project of significant interest seem to get no break.
I have strong feelings re. the MECHANISM that was used to gut development-stage biotechs, second quarter..... four biotechs with excellent research teams, note that three of the four splutted concurrently.
finance.yahoo.com
(first four stocks I picked, random except that I was trying to pick companies with innovative science and targets.... arna recovered early as it got go-ahead on a phase III.)
>> January Effect play. Anyone got thoughts on its potential in that context? <<
Looks like it is a good candidate for tax-selling, last couple of months. Tax sellers often are among the decent January performances, IMO.
No, I haven't followed it. But I have no doubt that PNP is a valid target for both lymphoid malignancies and for autoimmunity. With a RP of 300m, this baby will skyrocket if there's human-to-human transmission that looks problematic??????????
Sorry I can't be of more help. Thanks, very much, for the tickle. I'm interested, and will be interested in the ASH reports.
Rick |
